



Announcement Summary

Entity name

MAYNE PHARMA GROUP LIMITED

Date of this announcement

Tuesday January 03, 2023

The +securities the subject of this notification are:

☒ Other

Total number of +securities to be issued/transferred

ASX +security code	Security description	Total number of +securities to be issued/transferred	Issue date
New class - code to be confirmed	CONVERTIBLE NOTE	27,950	31/12/2022

Refer to next page for full details of the announcement



## Part 1 - Entity and announcement details

---

### 1.1 Name of entity

MAYNE PHARMA GROUP LIMITED

We (the entity named above) give notice of the issue, conversion or payment up of the following unquoted +securities.

### 1.2 Registered number type

ABN

### Registration number

76115832963

### 1.3 ASX issuer code

MYX

### 1.4 The announcement is

☒ New announcement

### 1.5 Date of this announcement

3/1/2023



Part 2 - Issue details

---

**2.1 The +securities the subject of this notification are:**

☒ Other

**Please specify**

Please refer to Appendix 3B dated 5 December 2022

**2.2a This notification is given in relation to an issue of +securities in a class which is not quoted on ASX and which:**

☒ does not have an existing ASX security code ("new class")



Part 3C - number and type of +securities the subject of this notification (new class) where issue has not previously been notified to ASX in an Appendix 3B

**New +securities****ASX +security code**

New class - code to be confirmed

**+Security description**

CONVERTIBLE NOTE

**+Security type**

+Convertible debt securities

**ISIN code****Date the +securities the subject of this notification were issued**

31/12/2022

**Will all the +securities issued in this class rank equally in all respects from their issue date?**☒ Yes**Have you received confirmation from ASX that the terms of the +securities are appropriate and equitable under listing rule 6.1?**☒ Yes**Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities being issued.**

Refer to cleansing notice provided on 30 December 2022: <https://www.asx.com.au/asx/statistics/displayAnnouncement.do?display=pdf&idsId=02617623>

**+Convertible debt securities Details****Type of +security**

Convertible note or bond

**+Security currency**

USD - US Dollar

**Face value**

USD 1,000.00000000

**Interest rate type**

Fixed rate

**Frequency of coupon/interest payments per year**

Quarterly

**First interest payment date**

31/3/2023

**Interest rate per annum**

2.50 %

**Is the interest rate per annum estimated at this time?**☒ No**s128F of the Income Tax Assessment Act status applicable to the +security**

s128F exemption status unknown

**Is the +security perpetual (i.e. no maturity)?**☒ No**Maturity date**

31/12/2026

**Select other feature(s) applicable to the +security**☒ Convertible**Is there a first trigger date on which a right of conversion, redemption, call or put can be exercised (whichever is first)?**☒ Yes**If yes, what is the first trigger date?**

30/6/2023

**Details of the existing class of +security that will be issued if the securities are converted, transformed or exchanged**

Other

**Description**

MYX - ORDINARY FULLY PAID

**Any other information the entity wishes to provide about the +securities the subject of this notification**

N/A

**Please provide any further information needed to understand the circumstances in which you are notifying the issue of these +securities to ASX, including why the issue of the +securities has not been previously announced to the market in an Appendix 3B**

Please refer to Appendix 3B dated 5 December 2022.

---

**Issue details****Number of +securities**

27,950

**Were the +securities issued for a cash consideration?**☒ Yes**In what currency was the cash consideration being paid?**

USD - US Dollar

**What was the issue price per +security?**

USD 1,000.00000000

**Purpose of the issue**

To pay for the acquisition of an asset

**Additional Details**

Refer to ASX Announcement dated 5 Dec 2022 for more details

**Name of company or asset being acquired**

Funds used to pay consideration for the exclusive license agreement with TherapeuticsMD Inc

Part 4 - +Securities on issue

---

Following the issue, conversion or payment up of the +securities the subject of this application, the +securities of the entity will comprise:  
(A discrepancy in these figures compared to your own may be due to a matter of timing if there is more than one application for quotation/issuance currently with ASX for processing.)

**4.1 Quoted +Securities (Total number of each +class of +securities quoted)**

ASX +security code and description	Total number of +securities on issue
MYX : ORDINARY FULLY PAID	1,739,815,508

**4.2 Unquoted +Securities (Total number of each +class of +securities issued but not quoted on ASX)**

ASX +security code and description	Total number of +securities on issue
MYXAN : PERFORMANCE RIGHTS	58,857,773
MYXAT : OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES	16,706,827
New class - code to be confirmed : CONVERTIBLE NOTE	27,950



Part 5 - Other Listing Rule requirements

---

**5.1 Were the +securities issued under an exception in Listing Rule 7.2 and therefore the issue did not need any security holder approval under Listing Rule 7.1?**

☒ No

**5.2 Has the entity obtained, or is it obtaining, +security holder approval for the issue under listing rule 7.1?**

☒ No

**5.2b Are any of the +securities being issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?**

☒ Yes

**5.2b.1 How many +securities are being issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?**

27,950 convertible notes

Upon conversion of the convertible notes, up to 178,863,974 ordinary shares

**5.2c Are any of the +securities being issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A (if applicable)?**

☒ N/A